Pediatric brain tumors

Innovative genomic information is transforming the diagnostic and clinical landscape

Amar Gajjar, Daniel C. Bowers, Matthias A. Karajannis, Sarah Leary, Hendrik Witt, Nicholas G. Gottardo

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Pediatric neuro-oncology has undergone an exciting and dramatic transformation during the past 5 years. This article summarizes data from collaborative group and institutional trials that have advanced the science of pediatric brain tumors and survival of patients with these tumors. Advanced genomic analysis of the entire spectrum of pediatric brain tumors has heralded an era in which stakeholders in the pediatric neuro-oncology community are being challenged to reconsider their current research and diagnostic and treatment strategies. The incorporation of this new information into the next-generation treatment protocols will unleash new challenges. This review succinctly summarizes the key advances in our understanding of the common pediatric brain tumors (ie, medulloblastoma, low- and high-grade gliomas, diffuse intrinsic pontine glioma, and ependymoma) and some selected rare tumors (ie, atypical teratoid/rhabdoid tumor and CNS primitive neuroectodermal tumor). The potential impact of this new information on future clinical protocols also is discussed. Cutting-edge genomics technologies and the information gained from such studies are facilitating the identification of molecularly defined subgroups within patients with particular pediatric brain tumors. The number of evaluable patients in each subgroup is small, particularly in the subgroups of rare diseases. Therefore, international collaboration will be crucial to draw meaningful conclusions about novel approaches to treating pediatric brain tumors.

Original languageEnglish (US)
Pages (from-to)2986-2998
Number of pages13
JournalJournal of Clinical Oncology
Volume33
Issue number27
DOIs
StatePublished - Sep 20 2015

Fingerprint

Brain Neoplasms
Pediatrics
Clinical Protocols
Glioma
Primitive Neuroectodermal Tumors
Ependymoma
Medulloblastoma
Rare Diseases
Genomics
Neoplasms
Spectrum Analysis
Technology
Survival
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pediatric brain tumors : Innovative genomic information is transforming the diagnostic and clinical landscape. / Gajjar, Amar; Bowers, Daniel C.; Karajannis, Matthias A.; Leary, Sarah; Witt, Hendrik; Gottardo, Nicholas G.

In: Journal of Clinical Oncology, Vol. 33, No. 27, 20.09.2015, p. 2986-2998.

Research output: Contribution to journalArticle

Gajjar, Amar ; Bowers, Daniel C. ; Karajannis, Matthias A. ; Leary, Sarah ; Witt, Hendrik ; Gottardo, Nicholas G. / Pediatric brain tumors : Innovative genomic information is transforming the diagnostic and clinical landscape. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 27. pp. 2986-2998.
@article{45cc57b70b8d4322ac69fd2da2cd1665,
title = "Pediatric brain tumors: Innovative genomic information is transforming the diagnostic and clinical landscape",
abstract = "Pediatric neuro-oncology has undergone an exciting and dramatic transformation during the past 5 years. This article summarizes data from collaborative group and institutional trials that have advanced the science of pediatric brain tumors and survival of patients with these tumors. Advanced genomic analysis of the entire spectrum of pediatric brain tumors has heralded an era in which stakeholders in the pediatric neuro-oncology community are being challenged to reconsider their current research and diagnostic and treatment strategies. The incorporation of this new information into the next-generation treatment protocols will unleash new challenges. This review succinctly summarizes the key advances in our understanding of the common pediatric brain tumors (ie, medulloblastoma, low- and high-grade gliomas, diffuse intrinsic pontine glioma, and ependymoma) and some selected rare tumors (ie, atypical teratoid/rhabdoid tumor and CNS primitive neuroectodermal tumor). The potential impact of this new information on future clinical protocols also is discussed. Cutting-edge genomics technologies and the information gained from such studies are facilitating the identification of molecularly defined subgroups within patients with particular pediatric brain tumors. The number of evaluable patients in each subgroup is small, particularly in the subgroups of rare diseases. Therefore, international collaboration will be crucial to draw meaningful conclusions about novel approaches to treating pediatric brain tumors.",
author = "Amar Gajjar and Bowers, {Daniel C.} and Karajannis, {Matthias A.} and Sarah Leary and Hendrik Witt and Gottardo, {Nicholas G.}",
year = "2015",
month = "9",
day = "20",
doi = "10.1200/JCO.2014.59.9217",
language = "English (US)",
volume = "33",
pages = "2986--2998",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "27",

}

TY - JOUR

T1 - Pediatric brain tumors

T2 - Innovative genomic information is transforming the diagnostic and clinical landscape

AU - Gajjar, Amar

AU - Bowers, Daniel C.

AU - Karajannis, Matthias A.

AU - Leary, Sarah

AU - Witt, Hendrik

AU - Gottardo, Nicholas G.

PY - 2015/9/20

Y1 - 2015/9/20

N2 - Pediatric neuro-oncology has undergone an exciting and dramatic transformation during the past 5 years. This article summarizes data from collaborative group and institutional trials that have advanced the science of pediatric brain tumors and survival of patients with these tumors. Advanced genomic analysis of the entire spectrum of pediatric brain tumors has heralded an era in which stakeholders in the pediatric neuro-oncology community are being challenged to reconsider their current research and diagnostic and treatment strategies. The incorporation of this new information into the next-generation treatment protocols will unleash new challenges. This review succinctly summarizes the key advances in our understanding of the common pediatric brain tumors (ie, medulloblastoma, low- and high-grade gliomas, diffuse intrinsic pontine glioma, and ependymoma) and some selected rare tumors (ie, atypical teratoid/rhabdoid tumor and CNS primitive neuroectodermal tumor). The potential impact of this new information on future clinical protocols also is discussed. Cutting-edge genomics technologies and the information gained from such studies are facilitating the identification of molecularly defined subgroups within patients with particular pediatric brain tumors. The number of evaluable patients in each subgroup is small, particularly in the subgroups of rare diseases. Therefore, international collaboration will be crucial to draw meaningful conclusions about novel approaches to treating pediatric brain tumors.

AB - Pediatric neuro-oncology has undergone an exciting and dramatic transformation during the past 5 years. This article summarizes data from collaborative group and institutional trials that have advanced the science of pediatric brain tumors and survival of patients with these tumors. Advanced genomic analysis of the entire spectrum of pediatric brain tumors has heralded an era in which stakeholders in the pediatric neuro-oncology community are being challenged to reconsider their current research and diagnostic and treatment strategies. The incorporation of this new information into the next-generation treatment protocols will unleash new challenges. This review succinctly summarizes the key advances in our understanding of the common pediatric brain tumors (ie, medulloblastoma, low- and high-grade gliomas, diffuse intrinsic pontine glioma, and ependymoma) and some selected rare tumors (ie, atypical teratoid/rhabdoid tumor and CNS primitive neuroectodermal tumor). The potential impact of this new information on future clinical protocols also is discussed. Cutting-edge genomics technologies and the information gained from such studies are facilitating the identification of molecularly defined subgroups within patients with particular pediatric brain tumors. The number of evaluable patients in each subgroup is small, particularly in the subgroups of rare diseases. Therefore, international collaboration will be crucial to draw meaningful conclusions about novel approaches to treating pediatric brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=84942250025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942250025&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.59.9217

DO - 10.1200/JCO.2014.59.9217

M3 - Article

VL - 33

SP - 2986

EP - 2998

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 27

ER -